Leap Therapeutics Inc
NASDAQ:LPTX

  • LAST PRICE
    2.4300
  • TODAY'S CHANGE (%)
    0.0700 (2.9661%)
  • Bid / Lots
    2.4300/ 4
  • Ask / Lots
    2.5000/ 15
  • Open / Previous Close
    2.3400 / 2.3600
  • Day Range
    2.3100
    2.4600
  • 52 Week Range
    1.2350
    10.2000
  • Volume
    153,944

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
LPTX
Leap Therapeutics Inc
93.0M
-1.0x
---
PMVP
PMV Pharmaceuticals Inc
93.6M
-1.4x
---
VOR
Vor Biopharma Inc
92.2M
-0.8x
---
IFRX
InflaRx NV
84.2M
-1.9x
---
GNLX
Genelux Corp
91.8M
-2.8x
---
RLMD
Relmada Therapeutics Inc
90.5M
-1.0x
---
As of 2024-06-02

Company Information

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Contact Information

Headquarters
47 Thorndike St Ste B1-1CAMBRIDGE, MA, United States 02141-1799
Phone
617-252-4343
Fax
302-636-5454

Executives

Chairman of the Board
Christopher Mirabelli
Chief Financial Officer, Treasurer, Secretary, Director
Douglas Onsi
Chief Operating Officer
Augustine Lawlor
Chief Scientific Officer
Jason Baum
Vice President, Head - Regulatory Affairs and Quality
Christine Granfield

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$93.0M
Revenue (TTM)
$0.00
Shares Outstanding
38.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.42
EPS
$-2.39
Book Value
$2.35
P/E Ratio
-1.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.